A mgen will invest $900 million in an expansion of its Central Ohio biomanufacturing operations, bringing total investment in the state to over $1.4 billion. With the addition of 350 new jobs, the ...

After topping up its long-running operations in Puerto Rico with plans for a $650 million investment last year, Amgen is infusing several hundred million dollars more into the U.S. territory. Amgen is ...

Amgen (NASDAQ: AMGN) today announced plans to invest an additional $300 million in its U.S. manufacturing network to further advance U.S.-based production capacity, enhance next-generation ...

Total Investment in the State to Exceed $1.4 Billion, 750 U.S. Jobs Since passage of the Tax Cuts and Jobs Act of 2017, Amgen has invested almost $5 billion in direct capital expenditures in the ...

The biotech company is increasing its capabilities at its Juncos manufacturing facility there.The global biotech company is ...

Amgen is investing an additional $300m into its Puerto Rico manufacturing operations, expanding U.S. biologics production ...

NEW ALBANY, Ohio (WCMH) — Biotechnology company Amgen announced a $900 million manufacturing expansion in Ohio on Friday, bringing 350 new jobs to central Ohio. Lt. Gov. Jim Tressel joined Amgen ...

Amgen (AMGN) stock dropped 1.54% as the biotech announced $300M for Puerto Rico expansion, part of a broader $3.65B+ U.S. manufacturing commitment.

THOUSAND OAKS, Calif., Dec. 5, 2024 /PRNewswire/ -- Amgen (AMGN) today announced a $1 billion expansion to establish a second drug substance manufacturing facility in North Carolina. This brings the ...

Thousand Oaks-based Amgen continues to invest in its onshore capabilities, after the biotech giant announced plans to invest an additional $300 million in its U.S. manufacturing network to further ...

(RTTNews) - Amgen, Inc. (AMGN) announced Monday the opening of its manufacturing site in Central Ohio, the newest in its global operations network and the most advanced facility to date. The nearly ...

In the last week, Amgen, Inc and Amgen Manufacturing Ltd, LLC (“Amgen”) filed three more BPCIA complaints against companies seeking approval for a denosumab biosimilar. On June 25, 2025, Amgen filed a ...